• Organization TypeService Providers
  • Staff10,000+
  • HeadquartersUnited States
  • Founded2013


AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and capabilities of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases. In 2013, AbbVie will employ approximately 21,000 people worldwide and markets medicines in more than 170 countries. AbbVie began as the pharmaceutical leader, Abbott, which was founded in 1888 by Chicago physician, Dr. Wallace Abbott. Since then, Abbott has evolved to become a global healthcare leader, delivering innovative pharmaceutical, nutritional, diagnostic, and medical products. Focus Areas Hepatitis C Virus (HCV) The antiviral program is focused on developing treatments for hepatitis C (HCV), a disease that affects more than 170 million people worldwide, with approximately 4 million people newly infected each year. HCV infections can potentially lead to long-term complications. AbbVie scientists are working to transform current treatment practices by investigating a new treatment regimen that is interferon-free for patients with genotype 1 HCV. AbbVie has several compounds for HCV in late-stage development, including protease, non-nucleoside polymerase, and NS5A inhibitors. Neuroscience AbbVie is conducting innovative research on compounds that target receptors in the brain, which help regulate pain, mood, memory and other neurological functions. AbbVie has a number of early and advanced investigational compounds in human studies for conditions such as schizophrenia, chronic pain, Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS) - all of which affect millions of people worldwide. Immunology AbbVie's scientific experience with biologics serves as a strong foundation for continuing research in immunology. AbbVie is investigating a number of additional diseases, including spondyloarthropathies, hidradenitis suppurativa, and uveitis, all of which are in late-stage development. The early discovery programs are focused on the investigation of both targeted oral therapies and biologics. AbbVie scientists are innovators in the antibody therapeutic field, with the creation and development of proprietary Dual-Variable Domain immunoglobulins (DVD-Ig), which allows for creating combination antibodies to simultaneously target multiple pathways responsible for disease progression. Oncology The oncology research is focused on the discovery and development of targeted therapies that work against the processes cancers need to survive. AbbVie is investigating both small- and large-molecule approaches, and the internal research efforts are balanced with external collaborations across industry, academia, and government. AbbVie's oncology pipeline includes multiple new molecules in clinical trials, being studied in more than 15 different cancers and tumor types, including some of the most widespread and difficult-to-treat cancers such as multiple myeloma and chronic lymphocytic leukemia. Renal Disease Chronic kidney disease (CKD), the progressive loss of kidney function, affects 50 million people in the U.S. and Europe alone. CKD is on the rise, driven by higher rates of diabetes, obesity and hypertension. AbbVie's renal care pipeline includes potential therapies for CKD and for acute kidney injury, a complication of major surgery that affects 1.2 million people at risk annually. Women’s Health AbbVie is currently focused on developing a compound for endometriosis and uterine fibroids, which each affect more than 16 million women worldwide. Both are highly prevalent conditions associated with a number of symptoms including pain and infertility. Because these conditions are undertreated, AbbVie has the potential to fill a significant therapeutic void.  
See more


Staff at AbbVie have experience in


  • development
  • private sector development
  • health systems
  • logistics / supplies
  • data management


  • test


  • hong kong
  • senegal
  • united states
  • canada
  • brazil


  • managerial experience
  • business development
  • international experience
  • with experience in conflict areas


Private Sector Development
Logistics / Supplies
Torts / Conflict Resolution
Trade Customs

Primary Funders

Contract Awards

Company Offices

  • United States (headquarters)
  • Chicago
  • 1 Waukegan Road North
  • Illinois 60064